EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Multiplex sample-sparing assay for detecting type-specific antibodies to Zika and dengue viruses: an assay development and validation study

Lindsay Dahora Hein, Izabella N Castillo, Freddy A Medina, Frances Vila, Bruno Segovia-Chumbez, Jorge L Muñoz-Jordán, Stephen S Whitehead, Laura E Adams, Gabriela Paz-Bailey, Aravinda M de Silva, Lakshmanane Premkumar

The Lancet Microbe · 2025-02 · 6 (2) · 100951

DOI: 10.1016/j.lanmic.2024.07.014 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift The Lancet Microbe, 2025-02. Verfasst von Lindsay Dahora Hein und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Dengue Virus, Zika Virus, Antibodies, Viral, Zika Virus Infection. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Centers for Disease Control and Prevention, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Serology for dengue viruses (DENV) and Zika virus (ZIKV) has been hindered by antibody cross-reactivity, which limits the utility of these tests for surveillance and assessment of sero-status. Our aim was to develop a multiplexed IgG-based assay with increased accuracy to assess the history of previous DENV and ZIKV infections. METHODS: We developed and assessed the analytical performance of a sample-sparing, multiplexed, microsphere-based serological assay using domain III of the envelope protein (EDIII) of DENV serotypes 1-4 and ZIKV, the most variable region between each virus. We used a reference panel of well-characterised serum samples from US-based travellers or residents of southeast Asia, central America, or Puerto Rico, who were naive or immune to either or both DENV and ZIKV, to develop an algorithm for detecting previous exposure to DENV and ZIKV and identify optimal positivity cutoffs to maximise assay performance. To independently confirm the performance of the assay and algorithm, we used a second test set of previously collected samples from healthy children (aged 9-16 years) living in Puerto Rico, whose DENV and ZIKV serostatus had been defined using the gold-standard virus neutralisation assay. We evaluated the performance of the multiplex assay compared with the gold-standard assay by estimating sensitivity and specificity for identification of past exposure to ZIKV and DENV. FINDINGS: The multiplexed EDIII assay showed reproducible results over different days and a linearity range from μg to pg levels for various EDIII antigens. Using a reference panel of serum samples from individuals who were DENV naive (n=136), DENV immune (n=38), ZIKV naive (n=67), and ZIKV immune (n=28), we optimised the assay and developed a testing algorithm that was 94·9% (95% CI 83·1-99·1) sensitive and 97·1% (92·7-98·9) specific for identifying previous exposure to DENV, and 100% (95% CI 88·0-100) sensitive and 97·0% (89·8-99·5) specific for identifying previous exposure to ZIKV. In an analysis with an independent test set of 389 samples, the assay and algorithm had 94·2% (89·9-97·1) sensitivity and 92·9% (87·3-96·5) specificity for DENV, and 94·1% (88·7-97·4) sensitivity and 95·0% (90·0-98·0) specificity for ZIKV. INTERPRETATION: The multiplexed EDIII serology assay can accurately identify the history of previous infection with either DENV or ZIKV. This high-throughput and sample-sparing assay is a promising new tool for supporting flavivirus surveillance, epidemiological and clinical studies, and serological testing for dengue vaccine eligibility. Further studies are needed to reduce the cost of the assay, eliminate high background in some samples, and to assess performance in DENV-endemic and ZIKV-endemic countries. FUNDING: US National Institutes of Health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dengue VirusZika VirusAntibodies, ViralZika Virus InfectionDengueSerologic TestsHumansChildAdolescentImmunoglobulin GSensitivity and SpecificityPuerto RicoCross ReactionsFemaleMaleViral Envelope ProteinsAlgorithms

Substanzen

Antibodies, ViralImmunoglobulin GViral Envelope Proteins

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Dengue Branch, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
  • Laboratory of Viral Diseases, NIAID, National Institutes of Health, Bethesda, MD, USA.
  • Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Electronic address: aravinda_desilva@med.unc.edu.
  • Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Electronic address: prem@med.unc.edu.

Förderung

  • NIAID NIH HHS
  • Centers for Disease Control and Prevention
  • NIH

Zitieren

APA

Hein, L. D., Castillo, I. N., Medina, F. A., Vila, F., Segovia-Chumbez, B., Muñoz-Jordán, J. L., Whitehead, S. S., Adams, L. E., Paz-Bailey, G., de Silva, A. M., & Premkumar, L. (2025). Multiplex sample-sparing assay for detecting type-specific antibodies to Zika and dengue viruses: an assay development and validation study. The Lancet Microbe, 6(2), 100951. https://doi.org/10.1016/j.lanmic.2024.07.014

Vancouver

Hein LD, Castillo IN, Medina FA, Vila F, Segovia-Chumbez B, Muñoz-Jordán JL, et al. Multiplex sample-sparing assay for detecting type-specific antibodies to Zika and dengue viruses: an assay development and validation study. The Lancet Microbe. 2025;6(2):100951. doi:10.1016/j.lanmic.2024.07.014

BibTeX
@article{Hein2025,
  author = {Hein, Lindsay Dahora and Castillo, Izabella N and Medina, Freddy A and Vila, Frances and Segovia-Chumbez, Bruno and Muñoz-Jordán, Jorge L and Whitehead, Stephen S and Adams, Laura E and Paz-Bailey, Gabriela and de Silva, Aravinda M and Premkumar, Lakshmanane},
  title = {Multiplex sample-sparing assay for detecting type-specific antibodies to Zika and dengue viruses: an assay development and validation study},
  journal = {The Lancet Microbe},
  year = {2025},
  volume = {6},
  number = {2},
  pages = {100951},
  doi = {10.1016/j.lanmic.2024.07.014}
}
Kostenlos starten →